SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Christopher Moylen who wrote (73)12/16/1996 12:32:00 PM
From: WWS   of 371
 
I am a shareholder of IMMU. But I consider IMMU to be "fully valued" at its present stock price. Actually, it is total market capitalization that is the critical factor, not stock price. There are over 30 million shares of IMMU, and these give IMMU a total capitalization of over $200 million. If you compare market cap with annual revenues you'll see that there are few biotechs with total market cap nearly 1/4 billion dollars that have negligible annual revenues, IMMU being one of the few. Pure and simple, what will elevate IMMU's present value is earnings (or at least increasing revenues). If IMMU's products begin to sell during the next year or so, then we'll see the stock respond. But I honestly don't think that there is much speculative (as opposed to earnings driven) upside potential left in IMMU at this time.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News